To read the full story, subscribe or sign in.

Yunovia cleared for Korea phase I trial of small-molecule GLP-1 asset

Sep. 3, 2024

Yunovia Co. Ltd. gained clearance in South Korea to start a multiple ascending dose phase I study for ID-110521156 – a novel, orally available, small-molecule, glucagon-like peptide-1 (GLP-1) agonist.

BioWorld Asia Clinical Cardiovascular Endocrine/metabolic Small molecule Asia-Pacific MOHW

Today's news in brief

BioWorld

BioWorld briefs for Sept. 12, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for September 13, 2024.

3D illustration of T cells fighting cancer

Highfield Biopharmaceuticals files IND in China for immunoliposome HF-50 for solid tumors

BioWorld Science

Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration (NMPA) to conduct a clinical trial of HF-50,...

Private labels, slow uptake mark first year of Humira biosimilars

BioWorld

Although last year’s massive U.S. launch of Humira biosimilars captured headlines, the market adoption of those competitors has been nothing to write home about,...

Big pharma eyes China ‘at forefront of GLP-1 revolution’

BioWorld

Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and...

Upgrade your daily dose of biopharma and medtech news

Yunovia cleared for Korea phase I trial of small-molecule GLP-1 asset